Medtech M&A remained active through the first half of 2026 as strategic buyers and private equity firms continued investing in and repositioning portfolios toward higher-growth categories. Disclosed deal value stayed on pace for another strong year following a decade-high 2025, supported by several scaled transactions. While geopolitical disruption and weaker equity performance increased caution across the sector, they did not materially change long-term investment priorities. Buyers continued focusing on assets that strengthen growth profiles, expand category positions, and build broader care-delivery capabilities.
Read the full article: PwC: Medtech – US Deals 2026 Midyear Outlook //
Source: https://www.pwc.com/us/en/industries/health-industries/library/medtech-deals-outlook.html